Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:AUPHNASDAQ:FLXNNYSE:LCINYSE:MYOV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.33-2.9%$1.59$0.68▼$2.48$278.46M0.794.26 million shs2.55 million shsAUPHAurinia Pharmaceuticals$4.87-3.2%$5.31$4.71▼$12.43$704.30M1.362.15 million shs1.53 million shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/ALCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-1.44%-38.01%-8.67%+91.77%AUPHAurinia Pharmaceuticals-1.18%+2.44%+0.80%-37.44%-54.56%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%LCILannett0.00%0.00%0.00%0.00%0.00%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.4499 of 5 stars3.52.00.04.01.10.80.6AUPHAurinia Pharmaceuticals1.1701 of 5 stars3.43.00.00.00.90.00.6FLXNFlexion Therapeutics0.2707 of 5 stars0.00.00.04.30.01.70.6LCILannettN/AN/AN/AN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00275.94% UpsideAUPHAurinia Pharmaceuticals2.75Moderate Buy$10.00105.34% UpsideFLXNFlexion TherapeuticsN/AN/AN/AN/ALCILannettN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest MYOV, FLXN, AUPH, LCI, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/1/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.002/23/2024AUPHAurinia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.002/22/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $13.002/16/2024AUPHAurinia PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold$9.50 ➝ $9.002/16/2024AUPHAurinia PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.43N/AN/A($0.16) per share-8.31AUPHAurinia Pharmaceuticals$175.51M4.01N/AN/A$2.63 per share1.85FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82LCILannett$340.58M0.00N/AN/A($23.34) per share0.00MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M-$0.54N/A8.85N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ALCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/AMYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ALatest MYOV, FLXN, AUPH, LCI, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AAUPHAurinia Pharmaceuticals-$0.17N/A+$0.17N/AN/AN/A 3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million2/15/202412/31/2023AUPHAurinia Pharmaceuticals-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03AUPHAurinia Pharmaceuticals0.205.504.99FLXNFlexion TherapeuticsN/A4.384.05LCILannettN/A2.231.39MYOVMyovant SciencesN/A1.571.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AUPHAurinia Pharmaceuticals36.83%FLXNFlexion Therapeutics90.01%LCILannett40.28%MYOVMyovant Sciences30.62%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%AUPHAurinia Pharmaceuticals4.30%FLXNFlexion Therapeutics9.13%LCILannett13.12%MYOVMyovant Sciences1.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableAUPHAurinia Pharmaceuticals300144.62 million138.40 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableLCILannett81010.77 million9.35 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableMYOV, FLXN, AUPH, LCI, and AKBA HeadlinesSourceHeadlineSalvage RT After Prostatectomy Prevails in Long-Term Comparison With Adjuvant RTmedpagetoday.com - April 19 at 7:59 PMWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugsuk.finance.yahoo.com - April 18 at 9:20 AMResearchers discover urine-based test to detect head and neck cancereurekalert.org - April 16 at 2:43 PMSocial Sciences & Interdisciplinary Studiescsus.edu - April 4 at 11:01 PMRoivant reveals positive immune drug data, share buyback plansbiopharmadive.com - April 2 at 3:38 PMComputer Science on Campusbc.edu - March 15 at 9:42 AMExposure to Teratogenic Medicine Common Before Prenatal Caremedpagetoday.com - February 6 at 9:50 AM2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Yearforbes.com - January 15 at 2:17 PMGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Regionfinance.yahoo.com - January 11 at 8:54 PMReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executivesfinance.yahoo.com - January 3 at 9:54 AMVivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...dailymail.co.uk - December 28 at 3:21 PMSumitomo Pharma CEO Myrtle Potter Focuses On Leading By Examplehealthleadersmedia.com - December 22 at 9:52 AMMetastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsightfinance.yahoo.com - December 8 at 9:34 AMDespite Effective Therapies, Fibroid Care Still Lackingmedscape.com - November 27 at 4:27 PMNCCN Announces Funding for Advanced Prostate Cancer Research Projectsmarkets.businessinsider.com - November 21 at 9:43 AMBlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in ...br.advfn.com - November 14 at 7:11 PMNews - Orgovyxthepharmaletter.com - October 24 at 3:11 PMNews - Myovant Sciencesthepharmaletter.com - October 24 at 3:11 PMMyovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbarrons.com - October 22 at 10:14 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant ...bakersfield.com - October 3 at 7:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVbenzinga.com - September 26 at 8:57 PMSumitomo Sued Over Skadden’s Alleged Conflicts in Myovant Mergernews.bloomberglaw.com - September 14 at 3:31 PM4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chiefmarketwatch.com - September 12 at 6:07 PMHormone Sensitive Advanced Prostate Cancer Treatment Market Set to Soar at 7.2% CAGR, Exceeding US$ 24.94 Billion by 2033 | Says FMIfmiblog.com - September 8 at 6:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia TreatmentAll Headlines Company DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Aurinia PharmaceuticalsNASDAQ:AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Myovant SciencesNYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.